Overall survival | Distant metastasis-free probability | |||
---|---|---|---|---|
Hazard ratio (95% confidence interval) | p-value | Hazard ratio (95% confidence interval) | p-value | |
BCMP11/ABCC11: Group 2 vs. Group 1 | 2.124 (1.0923 – 4.130) | 0.0260 | 1.759 (0.948 – 3.263) | 0.073 |
BCMP11/ABCC11: Group 3 vs. Group 1 | 2.155 (1.1874 – 3.913) | 0.0120 | 1.452 (0.817 – 2.580) | 0.200 |
Age (decade) | 0.688 (0.4792 – 0.988) | 0.0430 | 0.736 (0.523 – 1.035) | 0.078 |
Tumor diameter (cm) | 1.022 (0.9967 – 1.048) | 0.0890 | 1.034 (1.010 – 1.058) | 0.006 |
Lymph node status (positive node) | 1.010 (0.8309 – 1.228) | 0.9200 | 1.045 (0.886 – 1.234) | 0.600 |
Tumor grade: Poorly diff. vs. Intermediate | 1.185 (0.6586 – 2.131) | 0.5700 | 0.979 (0.560 – 1.713) | 0.940 |
Tumor grade: Well diff. vs. Intermediate | 0.240 (0.0828 – 0.698) | 0.0088 | 0.403 (0.190 – 0.855) | 0.018 |
Vascular invasion: 1–3 vessels vs. ≥ 4 vessels | 0.627 (0.2150 – 1.829) | 0.3900 | 0.530 (0.198 – 1.424) | 0.210 |
Vascular invasion: 0 vessels vs. ≥ 4 vessels | 0.589 (0.1322 – 2.621) | 0.4900 | 0.560 (0.145 – 2.158) | 0.400 |
Mastectomy vs. breast conserving therapy | 1.119 (0.6933 – 1.807) | 0.6400 | 1.193 (0.750 – 1.895) | 0.460 |
Chemo and hormonal therapy v. no adjuvant therapy | 0.724 (0.3281 – 0.1596) | 0.4200 | 0.502 (0.246 – 1.022) | 0.057 |